Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.41 |
| ▸ | OXTR | P30559 | 2/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 2/20 | 0.37 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.37 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.37 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.37 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.37 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729571 | 1.00 | CNR1 (0.41) | CNR1OXTRAVPR2AVPR1AMGLL | |
| SCHEMBL29839340 | 0.89 | CACNB4 (0.45) | CNR1OXTRAVPR2AVPR1AMGLL | |
| SCHEMBL22729645 | 0.89 | CACNB4 (0.45) | CNR1OXTRAVPR2AVPR1AMGLL | |
| SCHEMBL29839304 | 0.83 | MAPT (0.39) | CNR1OXTRAVPR2AVPR1AMGLL | |
| SCHEMBL22729599 | 0.83 | MAPT (0.39) | CNR1OXTRAVPR2AVPR1AMGLL | |
| SCHEMBL22729594 | 0.81 | SPR (0.38) | CNR1SPR | |
| SCHEMBL22729782 | 0.78 | UGCG (0.43) | CYP3A4 | |
| SCHEMBL23139902 | 0.78 | UGCG (0.42) | CYP3A4 | |
| SCHEMBL22729663 | 0.76 | KDM4E (0.45) | — | |
| SCHEMBL22729461 | 0.75 | KCNH2 (0.41) | CNR1SPRCYP3A4PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | CNR1 851/4885OXTR 4254/4885AVPR2 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.